BioSpace News Archive

Introduction of ImagingRing completes Elekta Studio, unleashing full potential of interventional radiotherapy

Presentations to highlight the OBI-833 Phase 1 clinical study results in non-small cell lung cancer (NSCLC) and the dose escalation cohort

Axonics Modulation Technologies, Inc., a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, is scheduled to participate in the Piper Sandler Virtual Healthcare Conference on December 1-2, 2020.

New Findings Show UroLift System Same-Day Outpatient Procedure Demonstrates Symptom Improvement for Benign Prostatic Hyperplasia

CSL Behring, a global biotherapeutics leader, announced survey results showing that a vast majority of HAE patients say it’s important their preventive therapy specifically corrects C1 esterase inhibitor deficiency.

Phosplatin Therapeutics LLC , a clinical stage pharmaceutical company focused on oncology therapeutics, today announced that data from a Phase I Dose Escalation Study of its lead candidate PT-112, an immunogenic cell death (ICD) inducer, in patients with relapsed or refractory multiple myeloma will be presented at the 62nd American So

Click Therapeutics announced today that Solera Health, the premier platform for addressing chronic conditions, will add Clickotine®, a clinically validated, fully digital smoking cessation program, for members of Blue Shield of California. Clicko

AstraZeneca Demonstrates Strength in Hematology With Robust Data at ASH 2020 Presentations support CALQUENCE efficacy and tolerability with long-term follow-up in mantle cell lymphoma and pooled safety data in chronic lymphocytic leukemia Emerging pipeline shows promise in novel targets and mechanisms to treat resistant and aggressive blood cancers

Tarus Therapeutics Inc., an innovative biotechnology company developing adenosine receptor antagonists for cancer immunotherapy and select non-oncology indications, today announced the appointments of Mark Cohen as Chairman of the Board, and Robert Glassman, MD PhD, as a new Board Director (effective January 1, 2021). Dr. Glassman has been a senior investment banker for 17 y

ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, Chief Executive Officer of the company, will participate in a fireside chat at the Piper Sandler 32 nd Annual Virtual Healthcare Conference being held from 30 November to 3 December 2020. A replay of the pre-recorded fireside chat will be available fr